title: Impact of IKZF1 deletions and PAX5 amplifications in pediatric B-cell precursor ALL treated according to NOPHO protocols.
authors.forename: I
authors.initials: I
authors.lastname: Ofverholm
authors.forename: A N
authors.initials: AN
authors.lastname: Tran
authors.forename: M
authors.initials: M
authors.lastname: Heyman
authors.forename: V
authors.initials: V
authors.lastname: Zachariadis
authors.forename: M
authors.initials: M
authors.lastname: Nordenskjöld
authors.forename: A
authors.initials: A
authors.lastname: Nordgren
authors.forename: G
authors.initials: G
authors.lastname: Barbany
mesh_terms: D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D002869:Chromosome Aberrations; D005260:Female; D005784:Gene Amplification; D017353:Gene Deletion; D006801:Humans; D051740:Ikaros Transcription Factor / Q000235:genetics*; D007223:Infant; D059785:Karyotype; D008297:Male; D051757:PAX5 Transcription Factor / Q000235:genetics*; D015452:Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy* / Q000235:genetics* / Q000401:mortality; D011379:Prognosis
chemical_list: C497239:IKZF1 protein, human; D051757:PAX5 Transcription Factor; C497281:PAX5 protein, human; D051740:Ikaros Transcription Factor